Compare FPH & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FPH | RZLT |
|---|---|---|
| Founded | 2009 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 300.7M | 352.1M |
| IPO Year | 2013 | 2011 |
| Metric | FPH | RZLT |
|---|---|---|
| Price | $4.48 | $3.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $10.10 |
| AVG Volume (30 Days) | 283.5K | ★ 1.3M |
| Earning Date | 10-22-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.47 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $110,020,000.00 | N/A |
| Revenue This Year | $1,459.63 | N/A |
| Revenue Next Year | $5.38 | N/A |
| P/E Ratio | $11.40 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.02 | $1.07 |
| 52 Week High | $6.47 | $11.17 |
| Indicator | FPH | RZLT |
|---|---|---|
| Relative Strength Index (RSI) | 52.50 | 41.77 |
| Support Level | $4.11 | $3.58 |
| Resistance Level | $4.64 | $4.22 |
| Average True Range (ATR) | 0.17 | 0.35 |
| MACD | 0.05 | 0.00 |
| Stochastic Oscillator | 70.27 | 12.09 |
Five Point Holdings LLC is an owner and developer of mixed-use, master-planned communities in California. It is engaged in developing new communities that, in addition to homesites, include commercial, retail, educational, and recreational elements, as well as civic areas, parks, and open spaces. Its four reportable segments are Valencia, San Francisco, Great Park, and Hearthstone. It derives the majority of revenue from the Great Park segment, which includes Great Park Neighborhoods being developed adjacent to and around the Orange County Great Park, a metropolitan park under construction in Orange County, California.
Rezolute Inc is a late-stage rare disease company focused on developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism. Its main clinical asset, Ersodetug, is a potential treatment for refractory hypoglycemia caused by multiple forms of hyperinsulinism. The company has a single reportable segment, which includes all of its activities as a clinical-stage biopharmaceutical company.